LAUSR

Tuberculosis (TB) is considered to be a significant health problem caused by Mycobacterium tuberculosis. It is one of the second-deadly infectious disease rights after AIDS. Several factors such as poor patient compliance, high dose intake, low drug bioavailability and prolonged treatment of disease are responsible for the prevalence of multi-drug resistance tuberculosis and extensively drug-resistant tuberculosis cases. Therefore, the development of such drug-resistant bacterial strains has created a robust and efficient system that can improve the therapeutic effectiveness of anti-tubercular drugs. This review manuscript highlights the therapeutic outcomes of nanotechnology-based drug delivery system in treating TB. Various novel nanoformulations for anti-mycobacterial drugs have been explored. Such novel approaches would have shown several advantages such as sustained/controlled drug release, reduced dose frequency, resolved poor patient compliance over many free anti-tubercular drugs. This framework will provide valuable information on various nanoparticle-based technology employed in treating infectious disease, TB.